Expanding insights of mitochondrial dysfunction in Parkinson's disease

Nature Reviews Neuroscience

Volumn 7, Issue 3, 2006, Pages 207-219

  Abou Sleiman, Patrick M ^a   Muqit, Miratul M K ^a   Wood, Nicholas W ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; LEUCINE; PARKIN; PHOSPHOTRANSFERASE; PROTEASOME; SERINE PROTEINASE OMI; UBIQUITIN;

AMINO TERMINAL SEQUENCE; APOPTOSIS; CELL DEATH; CELL FUNCTION; ENZYME ACTIVITY; GENE EXPRESSION; GENETICS; HOMOZYGOSITY; HUMAN; MITOCHONDRION; MUTATION; NERVE CELL; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PARKINSONISM; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REVIEW; SENSITIZATION; TOXICITY;

ALPHA-SYNUCLEIN; ANIMALS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MITOCHONDRIA; MITOCHONDRIAL DISEASES; MITOCHONDRIAL PROTEINS; MODELS, BIOLOGICAL; MULTIENZYME COMPLEXES; ONCOGENE PROTEINS; PARKINSON DISEASE; PROTEIN KINASES; SERINE ENDOPEPTIDASES; UBIQUITIN-PROTEIN LIGASES;

EID: 33644543761     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/nrn1868     Document Type: Review

References (141)

1. Spillantini, M. G. et al. α-Synuclein in Lewy bodies. Nature 388, 839-840 (1997). The first study to show α-synuclein in Lewy bodies, linking synuclein biology and dysfunction to sporadic PD.
2. Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K. & Seitelberger, F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20, 415-455 (1973).
3. Langston, J. W., Ballard, P., Tetrud, J. W. & Irwin, I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979-980 (1983). The first major study to show that MPTP can induce parkinsonism in humans.
4. Nicklas, W. J., Vyas, I. & Heikkila, R. E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36, 2503-2508 (1985).
5. Fiskum, G., Starkov, A., Polster, B. M. & Chinopoulos, C. Mitochondrial mechanisms of neural cell death and neuroprotective interventions in Parkinson's disease. Ann. NY Acad. Sci. 991, 111-119 (2003).
6. Mizuno, Y. et al. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem. Biophys. Res. Commun. 163, 1450-1455 (1989).
7. Parker, W. D. Jr, Boyson, S. J. & Parks, J. K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26, 719-723 (1989).
8. Schapira, A. H. et al. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1, 1269 (1989). The first study to show complex I deficiency in the brains of patients with PD, linking the MPTP model to sporadic PD.
9. Orth, M. & Schapira, A. H. Mitochondrial involvement in Parkinson's disease. Neurochem. Int. 40, 533-541 (2002).
10. Betarbet, R. et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nature Neurosci. 3, 1301-1306 (2000). Reports perhaps the best animal model of PD - parkinsonism in rats caused by the complex I inhibitor rotenone.
11. Thyagarajan, D. et al. A novel mitochondrial 12SrRNA point mutation in parkinsonism, deafness, and neuropathy. Ann. Neurol. 48, 730-736 (2000).
12. Luoma, P. et al. Parkinsonism, premature menopause, and mitochondrial DNA polymerase γ mutations: clinical and molecular genetic study. Lancet 364, 875-882 (2004).
13. Polymeropoulos, M. H. et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047 (1997). The first report of a single gene mutation resulting in PD.
14. Kitada, T. et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608 (1998).
15. Conway, K. A., Rochet, J. C., Bieganski, R. M. & Lansbury, P. T. Jr. Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct. Science 294, 1346-1349 (2001). An important paper showing that dopamine modulates α-synuclein aggregation, which suggests a mechanism for the regional selectivity of PD.
16. Bonifati, V. et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299, 256-259 (2003).
17. Valente, E. M. et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304, 1158-1160 (2004). The first report of a PD gene unequivocally localized to mitochondria.
18. Leroy, E. et al. The ubiquitin pathway in Parkinson's disease. Nature 395, 451-452 (1998).
19. Strauss, K. M. et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum. Mol. Genet. 14, 2099-2111 (2005).
20. Chandra, S., Gallardo, G., Fernandez-Chacon, R., Schluter, O. M. & Sudhof, T. C. α-Synuclein cooperates with CSPα in preventing neurodegeneration. Cell 123, 383-396 (2005). A groundbreaking study that suggests a role for α-synuclein in the prevention of neurodegeneration.
21. Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M. & Goedert, M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl Acad. Sci. USA 95, 6469-6473 (1998).
22. Conway, K. A., Harper, J. D. & Lansbury, P. T. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease. Nature Med. 4, 1318-1320 (1998).
23. Caughey B. & Lansbury, P. T. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 26, 267-298 (2003).
24. Lashuel, H. A., Hartley, D., Petre, B. M., Walz, T. & Lansbury, P. T. Jr. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418, 291 (2002).
25. Miller, D. W. et al. α-Synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 62, 1835-1838 (2004).
26. Farrer, M. et al. α-Synuclein gene haplotypes are associated with Parkinson's disease. Hum. Mol. Genet. 10, 1847-1851 (2001).
27. Fujiwara, H. et al. α-Synuclein is phosphorylated in synucleinopathy lesions. Nature Cell Biol. 4, 160-164 (2002). An important study showing that phosphorylation of synuclein at Ser129 may mediate pathogenicity of synuclein in vivo.
28. Chen, L. & Feany, M. B. α-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nature Neurosci. 8, 657-663 (2005).
29. Feany, M. B. & Bender, W. W. A Drosophila model of Parkinson's disease. Nature 404, 394-398 (2000).
30. Masliah, E. et al. Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265-1269 (2000).
31. Giasson, B. I. et al. Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein. Neuron 34, 521-533 (2002).
32. Lee, M. K. et al. Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice. Proc. Natl Acad. Sci. USA 99, 8968-8973 (2002).
33. Auluck, P. K., Chan, H. Y., Trojanowski, J. Q., Lee, V. M. & Bonini, N. M. Chaperone suppression of α-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295, 865-868 (2002).
34. Lo Bianco, C. et al. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an α-synuclein rat model of Parkinson's disease. Proc. Natl Acad. Sci. USA 101, 17510-17515 (2004).
35. Oluwatosin-Chigbu, Y. et al. Parkin suppresses wildtype α-synuclein-induced toxicity in SHSY-5Y cells. Biochem. Biophys. Res. Commun. 309, 679-684 (2003).
36. Goedert, M. α-Synuclein and neurodegenerative diseases. Nature Rev. Neurosci. 2, 492-501 (2001).
37. Orth, M. & Tabrizi, S. J. Models of Parkinson's disease. Mov. Disord. 18, 729-737 (2003).
38. Tabrizi, S. J. et al. Expression of mutant α-synuclein causes increased susceptibility to dopamine toxicity. Hum. Mol. Genet. 9, 2683-2689 (2000).
39. Dauer, W. et al. Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl Acad. Sci. USA 99, 14524-14529 (2002).
40. Klivenyi, P. et al. Mice lacking α-synuclein are resistant to mitochondrial toxins. Neurobiol. Dis. 17 Nov 2005 (doi:10.1016/j.nbd.2005.08. 018).
41. Sulzer, D. et al. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc. Natl Acad. Sci. USA 97, 11869-11874 (2000).
42. Abbas, N. et al. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. Hum. Mol. Genet. 8, 567-574 (1999).
43. Lucking, C. B. et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group. N. Engl. J. Med. 342, 1560-1567 (2000).
44. Shimura, H. et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nature Genet. 25, 302-305 (2000).
45. Sakata, E. et al. Parkin binds the Rpn10 subunit of 26S proteasomes through its ubiquitin-like domain. EMBO Rep. 4, 301-306 (2003).
46. Ciechanover, A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J. 17, 7151-1760 (1998).
47. Farrer, M. et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann. Neurol. 50, 293-300 (2001).
48. Muftuoglu, M. et al. Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations. Mov. Disord. 19, 544-548 (2004).
49. Shimura, H. et al. Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. Ann. Neurol. 45, 668-672 (1999).
50. Schlossmacher, M. G. et al. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am. J. Pathol. 160, 1655-1667 (2002).
51. Greene, J. C. et al. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc. Natl Acad. Sci. USA 100, 4078-4083 (2003). The first study to link parkin to mitochondrial dysfunction.
52. Greene, J. C., Whitworth, A. J., Andrews, L. A., Parker, T. J. & Pallanck, L. J. Genetic and genomic studies of Drosophila parkin mutants implicate oxidative stress and innate immune responses in pathogenesis. Hum. Mol. Genet. 14, 799-811 (2005).
53. Whitworth, A. J. et al. Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson's disease. Proc. Natl Acad. Sci. USA 102, 8024-8029 (2005).
54. Palacino, J. J. et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem. 279, 18614-18622 (2004).
55. Goldberg, M. S. et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J. Biol. Chem. 278, 43628-43635 (2003).
56. Itier, J. M. et al. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum. Mol. Genet 12, 2277-2291 (2003).
57. Perez, F. A. & Palmiter, R. D. Parkin-deficient mice are not a robust model of parkinsonism. Proc. Natl Acad. Sci. USA 102, 2174-2179 (2005).
58. 18F]dopa PET and clinical study. Brain 125, 2248-2256 (2002).
59. Darios, F. et al. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum. Mol. Genet. 12, 517-526 (2003).
60. Casellas, P., Galiegue, S. & Basile, A. S. Peripheral benzodiazepine receptors and mitochondrial function. Neurochem. Int. 40, 475-486 (2002).
61. Zhaung, Z. P. & McCauley, R. Ubiquitin is involved in the in vitro insertion of monoamine oxidase B into mitochondrial outer membranes. J. Biol. Chem. 264, 14594-14596 (1989).
62. Takahashi, R., Imai, Y., Hattori, N. & Mizuno, Y. Parkin and endoplasmic reticulum stress. Ann. NY Acad. Sci. 991, 101-106 (2003).
63. Yamanaka, K. et al. Identification of the ubiquitin-protein ligase that recognizes oxidized IRP2. Nature Cell Biol. 5, 336-340 (2003).
64. Hyun, D. H., Lee, M., Halliwell, B. & Jenner, P. Effect of overexpression of wild-type or mutant parkin on the cellular response induced by toxic insults. J. Neurosci. Res. 82, 232-244 (2005).
65. Chung, K. K. et al. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science 304, 1328-1331 (2004).
66. Yao, D. et al. Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc. Natl Acad. Sci. USA 101, 10810-10814 (2004).
67. LaVoie, M. J., Ostaszewski, B. L., Weihofen, A., Schlossmacher, M. G. & Selkoe, D. J. Dopamine covalently modifies and functionally inactivates parkin. Nature Med. 11, 1214-1221 (2005). An important study showing that parkin activity is inactivated by dopamine, which suggests a mechanism for parkin dysfunction in sporadic PD.
68. Wang, C. et al. Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function. Hum. Mol. Genet. 14, 3885-3897 (2005).
69. Kalia, S. K. et al. BAG5 inhibits parkin and enhances dopaminergic neuron degeneration. Neuron 44, 931-945 (2004).
70. Robinson, P. A. & Ardley, H. C. Ubiquitin-protein ligases. J. Cell Sci. 117, 5191-5194 (2004).
71. von Coelln, R., Dawson, V. L. & Dawson, T. M. Parkin-associated Parkinson's disease. Cell Tissue Res. 318, 175-184 (2004).
72. Dong, Z. et al. Dopamine-dependent neurodegeneration in rats induced by viral vector-mediated overexpression of the parkin target protein, CDCrel-1. Proc. Natl Acad. Sci. USA 100, 12438-12443 (2003).
73. Yang, Y., Nishimura, I., Imai, Y., Takahashi, R. & Lu, B. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron 37, 911-924 (2003).
74. Imai, Y. et al. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 105, 891-902 (2001).
75. Choi, P. et al. SEPT5_v2 is a parkin-binding protein. Brain Res. Mol. Brain Res. 117, 179-189 (2003).
76. Ko, H. S. et al. Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J. Neurosci. 25, 7968-7978 (2005).
77. Petrucelli, L. et al. Parkin protects against the toxicity associated with mutant α-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 36, 1007-1019 (2002).
78. Shimura, H. et al. Ubiquitination of a new form of α-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293, 263-269 (2001).
79. Abou-Sleiman, P. M., Healy, D. G., Quinn, N., Lees, A. J. & Wood, N. W. The role of pathogenic DJ-1 mutations in Parkinson's disease. Ann. Neurol. 54, 283-286 (2003).
80. Rizzu, P. et al. DJ-1 colocalizes with tau inclusions: a link between parkinsonism and dementia. Ann. Neurol. 55, 113-118 (2004).
81. Bandopadhyay, R. et al. The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain 127, 420-430 (2004).
82. Junn, E. et al. Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death. Proc. Natl Acad. Sci. USA 102, 9691-9696 (2005).
83. Zhang, L. et al. Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Hum. Mol. Genet. 14, 2063-2073 (2005).
84. Cookson, M. R. The biochemistry of Parkinson's disease. Annu. Rev. Biochem. 74, 29-52 (2005).
85. Nagakubo, D. et al. DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem. Biophys. Res. Commun. 231, 509-513 (1997).
86. Hod, Y., Pentyala, S. N., Whyard, T. C. & El-Maghrabi, M. R. Identification and characterization of a novel protein that regulates RNA-protein interaction. J. Cell Biochem. 72, 435-444 (1999).
87. Mitsumoto, A. & Nakagawa, Y. DJ-1 is an indicator for endogenous reactive oxygen species elicited by endotoxin. Free Radic. Res. 35, 885-893 (2001).
88. Canet-Aviles, R. M. et al. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc. Natl Acad. Sci. USA 101, 9103-9108 (2004).
89. Yang, Y. et al. Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. Proc. Natl Acad. Sci. USA 102, 13670-13675 (2005).
90. Meulener, M. et al. Drosophila DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinson's disease. Curr. Biol. 15, 1572-1577 (2005).
91. Yokota, T. et al. Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition. Biochem. Biophys. Res. Commun. 312, 1342-1348 (2003).
92. Kim, R. H. et al. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc. Natl Acad. Sci. USA 102, 5215-5220 (2005).
93. Kim, R. H. et al. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell 7, 263-273 (2005).
94. Xu, J. et al. The Parkinson's disease-associated DJ-1 protein is a transcriptional co-activator that protects against neuronal apoptosis. Hum. Mol. Genet. 14, 1231-1241 (2005).
95. Shinbo, Y., Taira, T., Niki, T., Iguchi-Ariga, S. M. & Ariga, H. DJ-1 restores p53 transcription activity inhibited by Topors/p53BP3. Int. J. Oncol. 26, 641-648 (2005).
96. Honbou, K. et al. The crystal structure of DJ-1, a protein related to male fertility and Parkinson's disease. J. Biol. Chem. 278, 31380-31384 (2003).
97. Tao, X. & Tong, L. Crystal structure of human DJ-1, a protein associated with early onset Parkinson's disease. J. Biol. Chem. 278, 31372-31379 (2003).
98. Wilson, M. A., Collins, J. L., Hod, Y., Ringe, D. & Petsko, G. A. The 1.1-Å resolution crystal structure of DJ-1, the protein mutated in autosomal recessive early onset Parkinson's disease. Proc. Natl Acad. Sci. USA 100, 9256-9261 (2003).
99. Miller, D. W. et al. L166P mutant DJ-1, causative for recessive Parkinson's disease, is degraded through the ubiquitin-proteasome system. J. Biol. Chem. 278, 36588-36595 (2003).
100. Macedo, M. G. et al. The DJ-1L166P mutant protein associated with early onset Parkinson's disease is unstable and forms higher-order protein complexes. Hum. Mol. Genet. 12, 2807-2816 (2003).
101. Moore, D. J., Zhang, L., Dawson, T. M. & Dawson, V. L. A missense mutation (L166P) in DJ-1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homo-oligomerization. J. Neurochem. 87, 1558-1567 (2003).
102. Shendelman, S., Jonason, A., Martinat, C., Leete, T. & Abeliovich, A. DJ-1 is a redox-dependent molecular chaperone that inhibits α-synuclein aggregate formation. PLoS Biol. 2, e362 (2004).
103. Unoki, M. & Nakamura, Y. Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene 20, 4457-4465 (2001).
104. Nakajima, A., Kataoka, K., Hong, M., Sakaguchi, M. & Huh, N. H. BRPK, a novel protein kinase showing increased expression in mouse cancer cell lines with higher metastatic potential. Cancer Lett. 201, 195-201 (2003).
105. Silvestri, L. et al. Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum. Mol. Genet. 14, 3477-3492 (2005).
106. Rogaeva, E. et al. Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch. Neurol. 61, 1898-1904 (2004).
107. Bonifati, V. et al. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology 65, 87-95 (2005).
108. Beilina, A. et al. Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. Proc. Natl Acad. Sci. USA 102, 5703-5708 (2005).
109. Li, Y. et al. Clinicogenetic study of PINK1 mutations in autosomal recessive early-onset parkinsonism. Neurology 64, 1955-1957 (2005).
110. Chacinska, A., Pfanner, N. & Meisinger, C. How mitochondria import hydrophilic and hydrophobic proteins. Trends Cell Biol. 12, 299-303 (2002).
111. Hanks, S. K. & Hunter, T. Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J. 9, 576-596 (1995).
112. Petit, A. et al. Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson's disease-related mutations. J. Biol. Chem. 280, 34025-34032 (2005).
113. Schulenberg, B., Aggeler, R., Beechem, J. M., Capaldi, R. A. & Patton, W. F. Analysis of steady-state protein phosphorylation in mitochondria using a novel fluorescent phosphosensor dye. J. Biol. Chem. 278, 27251-27255 (2003).
114. Chen, R., Fearnley, I. M., Peak-Chew, S. Y. & Walker, J. E. The phosphorylation of subunits of complex I from bovine heart mitochondria. J. Biol. Chem. 279, 26036-26045 (2004).
115. Kokoszka, J. E. et al. The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. Nature 427, 461-465 (2004).
116. Gray, C. W. et al. Characterization of human HtrA2, a novel serine protease involved in the mammalian cellular stress response. Eur. J. Biochem. 267, 5699-5710 (2000).
117. Park, H. J., Seong, Y. M., Choi, J. Y., Kang, S. & Rhim, H. Alzheimer's disease-associated amyloid β interacts with the human serine protease HtrA2/Omi. Neurosci. Lett. 357, 63-67 (2004).
118. Martins, L. M. et al. Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Mol. Cell Biol. 24, 9848-9862 (2004).
119. Paisan-Ruiz, C. et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600 (2004).
120. Zimprich, A. et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601-607 (2004).
121. Gilks, W. P. et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365, 415-416 (2005).
122. West, A. B. et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl Acad. Sci. USA 102, 16842-16847 (2005).
123. Gloeckner, C. J. et al. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Genet. 15, 223-232 (2005).
124. Smith, W. W. et al. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc. Natl Acad. Sci. USA 102, 18676-18681 (2005).
125. Tatton, W. G., Chalmers-Redman, R., Brown, D. & Tatton, N. Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann. Neurol. 53 (Suppl. 3), S61-S70; discussion S70-S72 (2003).
126. Vila, M. & Przedborski, S. Targeting programmed cell death in neurodegenerative diseases. Nature Rev. Neurosci. 4, 365-375 (2003).
127. Bowling, A. C. & Beal, M. F. Bioenergetic and oxidative stress in neurodegenerative diseases. Life Sci. 56, 1151-1171 (1995).
128. Jazwinski, S. M. Genetics of longevity. Exp. Gerontol. 33, 773-783 (1998).
129. Khalyavkin, A. V. & Yashin, A. I. How the analysis of genetic mutations can help us to solve basic problems in gerontology? II. Life extending genetic modifications in budding yeast S. cereviseae, fruit fly D. melanogaster and laboratory mice M. musculus. Adv. Gerontol. 12, 46-56 (2003).
130. Hoglinger, G. U. et al. Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease. J. Neurochem. 86, 1297-1307 (2003).
131. Sullivan, P. G. et al. Proteasome inhibition alters neural mitochondrial homeostasis and mitochondria turnover. J. Biol. Chem. 279, 20699-20707 (2004).
132. Beal, M. F. Limited-time exposure to mitochondrial toxins may lead to chronic progressive neurodegenerative diseases. Mov. Disord. 15, 434-535 (2000).
133. McNaught, K. S., Perl, D. P., Brownell, A. L. & Olanow, C. W. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann. Neurol. 56, 149-162 (2004).
134. Shamoto-Nagai, M. et al. An inhibitor of mitochondrial complex I, rotenone, inactivates proteasome by oxidative modification and induces aggregation of oxidized proteins in SH-SY5Y cells. J. Neurosci. Res. 74, 589-597 (2003).
135. Oiu, J. H. et al. Proteasome inhibitors induce cytochrome c-caspase-3-like protease-mediated apoptosis in cultured cortical neurons. J. Neurosci. 20, 259-265 (2000).
136. Tanaka, Y. et al. Inducible expression of mutant α-synuclein decreases proteasome activity and increases sensitivity to mitochondria- dependent apoptosis. Hum. Mol. Genet. 10, 919-926 (2001).
137. Jesenberger, V. & Jentsch, S. Deadly encounter: ubiquitin meets apoptosis. Nature Rev. Mol. Cell Biol. 3, 112-121 (2002).
138. Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. Nature 408, 307-310 (2000).
139. Moore, D. J. et al. Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Hum. Mol. Genet. 14, 71-84 (2005).
140. Nicholls, D. G. Mitochondrial function and dysfunction in the cell: its relevance to aging and aging-related disease. Int. J. Biochem. Cell Biol. 34, 1372-1381 (2002).
141. Duchen, M. R. Mitochondria in health and disease: perspectives on a new mitochondrial biology. Mol. Aspects Med. 25, 365-451 (2004).